Biologics-based therapy for the treatment of rheumatoid arthritis

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 1, 2012, Pages 30-43

  Scott, D L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ARTHRITIS; B LYMPHOCYTE; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE ACTIVITY; DISEASE DURATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; IMMUNOCOMPETENT CELL; INFECTION; INFECTION RISK; LIVER TOXICITY; LYMPHOMA; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; HUMANS; TREATMENT OUTCOME;

EID: 84055164237     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.278     Document Type: Review

References (75)

1. Scott, D.L., Wolfe, F. & Huizinga, T.W. Rheumatoid arthritis. Lancet 376, 1094-1108 (2010).
2. Symmons, D. et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 41, 793-800 (2002). (Pubitemid 34822963)
3. Englund, M., Jüd, A., Geborek, P., Felson, D.T., Jacobsson, L.T. & Petersson, I.F. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford) 49, 1563-1569 (2010).
4. Pedersen, J.K., Kjaer, N.K., Svendsen, A.J. & Hslev-Petersen, K. Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatol. Int. 29, 411-415 (2009).
5. National Audit Office. Services for People with Rheumatoid Arthritis (2009).
6. Dougados, M., Aletaha, D. & van Riel, P. Disease activity measures for rheumatoid arthritis. Clin. Exp. Rheumatol. 25, S22-S29 (2007). (Pubitemid 350176264)
7. A letaha, D. & Smolen, J.S. The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. Rheum. Dis. Clin. North Am. 35, 759-72, viii (2009).
8. Wolfe, F., Michaud, K., Pincus, T., Furst, D. & Keystone, E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of antitumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. 52, 3873-3879 (2005). (Pubitemid 41798226)
9. Symmons, D.P. Rheumatoid arthritis: assessing disease activity and outcome. Clin. Med. 10, 248-251 (2010).
10. Y azici, Y., Sokka, T. & Pincus, T. Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. Rheum. Dis. Clin. North Am. 35, 723-729, vi (2009).
11. Boutry, N., Morel, M., Flipo, R.M., Demondion, X. & Cotten, A. Early rheumatoid arthritis: a review of MRI and sonographic findings. AJR. Am. J. Roentgenol. 189, 1502-1509 (2007). (Pubitemid 350174822)
12. Wells, G.A. Patient-driven outcomes in rheumatoid arthritis. J. Rheumatol. Suppl. 82, 33-38 (2009).
13. Christie, A., Jamtvedt, G., Dahm, K.T., Moe, R.H., Haavardsholm, E.A. & Hagen, K.B. Effectiveness of nonpharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews. Phys. Ther. 87, 1697-1715 (2007). (Pubitemid 350230760)
14. Donahue, K.E. et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann. Intern. Med. 148, 124-134 (2008). (Pubitemid 351651555)
15. Haraoui, B. et al.; the Treat to Target Taskforce. Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Ann. Rheum. Dis. 70, 1999-2002 (2011).
16. Felson, D.T. et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis. 70, 404-413 (2011).
17. Choy, E.H. & Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001). (Pubitemid 32224400)
18. Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2, 364-371 (2002). (Pubitemid 37328759)
19. Maini, R.N. Anti-TNF therapy from the bench to the clinic: a paradigm of translational research. Clin. Med. 10, 161-162 (2010).
20. Silverman, G.J. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum. 54, 2356-2367 (2006). (Pubitemid 44204995)
21. Kalliolias, G.D. & Liossis, S.N. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin. Investig. Drugs 17, 349-359 (2008). (Pubitemid 351578187)
22. Weinblatt, M.E. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-259 (1999). (Pubitemid 29063266)
23. Lipsky, P.E. et al.; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594-1602 (2000). (Pubitemid 32162982)
24. Scott, D.L. & Cope, A. New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? Ann. Rheum. Dis. 68, 767-769 (2009).
25. St Clair, E.W. et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 1451-1459 (2002).
26. Mima, T. & Nishimoto, N. Clinical value of blocking IL-6 receptor. Curr. Opin. Rheumatol. 21, 224-230 (2009).
27. Korhonen, R. & Moilanen, E. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. Basic Clin. Pharmacol. Toxicol. 106, 13-21 (2010).
28. Reparon-Schuijt, C.C., van Esch, W.J., van Kooten, C., Levarht, E.W., Breedveld, F.C. & Verweij, C.L. Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis Rheum. 41, 2211-2220 (1998). (Pubitemid 29009380)
29. Pham, T. et al. Abatacept therapy and safety management. Joint Bone Spine 76 (suppl. 1), S3-S55 (2009).
30. Blumenauer, B. et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. CD003785 (2002).
31. Blumenauer, B. et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. CD004525 (2003).
32. Navarro-Sarabia, F., Ariza-Ariza, R., Hernandez-Cruz, B. & Villanueva, I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst. Rev. CD005113 (2005).
33. Ruiz Garcia, V. et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst. Rev. CD007649 (2011).
34. Singh, J.A., Noorbaloochi, S. & Singh, G. Golimumab for rheumatoid arthritis. Cochrane Database Syst. Rev. CD008341 (2010).
35. Singh, J.A., Beg, S. & Lopez-Olivo, M.A. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst. Rev. CD008331 (2010).
36. Maxwell, L. & Singh, J.A. Abatacept for rheumatoid arthritis. Cochrane Database Syst. Rev. CD007277 (2009).
37. Lee, Y.H., Bae, S.C. & Song G.G. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and metaanalysis of randomized controlled trials. Rheumatol Int. (in press).
38. Nam, J.L. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 69, 976-986 (2010).
39. Singh, J.A. et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst. Rev. CD007848 (2009).
40. Lloyd, S., Bujkiewicz, S., Wailoo, A.J., Sutton, A.J. & Scott, D. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford). 49, 2313-2321 (2010).
41. Blum, M.A., Koo, D. & Doshi, J.A. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin. Ther. 33, 901-913 (2011).
42. Ma, M.H., Kingsley, G.H. & Scott, D.L. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 49, 91-98 (2010).
43. Y azici, Y., Moniz Reed, D., Klem, C., Rosenblatt, L., Wu, G. & Kremer, J.M. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Clin. Exp. Rheumatol. 29, 494-499 (2011).
44. Emery, P. et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann. Rheum. Dis. 69, 510-516 (2010).
45. Rahman, M.U. et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann. Rheum. Dis. 70, 1631-1640 (2011).
46. Graudal, N. & J-gens, G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 62, 2852-2863 (2010).
47. Kuriya, B., Arkema, E.V., Bykerk, V.P. & Keystone, E.C. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann. Rheum. Dis. 69, 1298-1304 (2010).
48. Jobanputra, P., Barton, P., Bryan, S. & Burls, A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. 6, 1-110 (2002).
49. A letaha, D., Strand, V., Smolen, J.S. & Ward, M.M. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann. Rheum. Dis. 67, 238-243 (2008). (Pubitemid 351183315)
50. G-fe, A., Kristensen, L.E., Saxne, T., Jacobsson, L.T., Petersson, I.F. & Geborek, P. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from southern Sweden. Arthritis Care Res. (Hoboken) 62, 1399-1406 (2010).
51. Khraishi, M. Comparative overview of safety of the biologics in rheumatoid arthritis. J. Rheumatol. Suppl. 82, 25-32 (2009).
52. Singh, J.A. et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. CD008794 (2011).
53. Leombruno, J.P., Einarson, T.R. & Keystone, E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposureadjusted pooled analyses of serious adverse events. Ann. Rheum. Dis. 68, 1136-1145 (2009).
54. Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L. & Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006). (Pubitemid 43736578)
55. Galloway, J.B. et al.; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50, 124-131 (2011).
56. Dixon, W.G. et al.; B S R B R Control Centre Consortium; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 69, 522-528 (2010).
57. Strangfeld, A. et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301, 737-744 (2009).
58. Clifford, D.B. et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 68, 1156-1164 (2011).
59. Solomon, D.H., Mercer, E. & Kavanaugh, A. Observational studies on the risk of cancer associated with TNF-inhibitors in RA: a review of their methodologies and results. Arthritis Rheum. (2011) (in press).
60. Verstappen, S.M., King, Y., Watson, K.D., Symmons, D.P. & Hyrich, K.L.; BSRBR Control Centre Consortium, BSR Biologics Register. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 70, 823-826 (2011).
61. Furst, D.E. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann. Rheum. Dis. 69 (suppl. 1), i2-29 (2010).
62. Hle, P., Straub, R.H. & Fleck, M. Perioperative management of immunosuppression in rheumatic diseases-what to do? Rheumatol. Int. 30, 999-1004 (2010).
63. Bendtzen, K. Is there a need for immunopharmacologic guidance of antitumor necrosis factor therapies? Arthritis Rheum. 63, 867-870 (2011).
64. Strangfeld, A. et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann. Rheum. Dis. 68, 1856-1862 (2009).
65. Marra, C.A., Bansback, N., Anis, A.H. & Shojania, K. Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clin. Rheumatol. 30 (suppl. 1), S9-18 (2011).
66. Schoels, M. et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69, 995-1003 (2010).
67. Brennan, A. et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 46, 1345-1354 (2007). (Pubitemid 47244512)
68. van der Velde, G. et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res. (Hoboken) 63, 65-78 (2011).
69. Goekoop-Ruiterman, Y.P. et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146, 406-415 (2007). (Pubitemid 351650575)
70. Kingsley, G.H., Khoshaba, B., Smith, C.M., Choy, E.H. & Scott, D.L. Are clinical trials in rheumatoid arthritis generalizable to routine practice? A reevaluation of trial entry criteria. Rheumatology (Oxford) 44, 629-632 (2005). (Pubitemid 41487232)
71. Wolfe, F. & Michaud, K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res. Ther. 12, R35 (2010).
72. Chatzidionysiou, K. & van Vollenhoven, R.F. When to initiate and discontinue biologic treatments for rheumatoid arthritis? J. Intern. Med. 269, 614-625 (2011).
73. Saag, K.G. et al.; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762-784 (2008). (Pubitemid 351847559)
74. Smolen, J.S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs. Ann. Rheum. Dis. (in press).
75. Deighton, C., O'Mahony, R., Tosh, J., Turner, C. & Rudolf, M.; Guideline Development Group. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 338, b702 (2009).